Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity Against Breast Cancer Models Resistant to Anti-Her2 Drugs

PLoS ONE - United States
doi 10.1371/journal.pone.0131241
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Antitumor Activity of Phenethyl Isothiocyanate in HER2-positive Breast Cancer Models

BMC Medicine
Medicine
2012English

TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Dual HER2 Blockade: Preclinical and Clinical Data

Breast Cancer Research
Cancer ResearchOncology
2014English

ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2014English

Developing Anti-Her2 Vaccines: Breast Cancer Experience

International Journal of Cancer
Cancer ResearchOncology
2018English

EGFR and HER2 Signaling in Breast Cancer Brain Metastasis

Frontiers in Bioscience - Elite
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2016English

The mTOR Inhibitor Rapamycin Synergizes With a Fatty Acid Synthase Inhibitor to Induce Cytotoxicity in ER/HER2-Positive Breast Cancer Cells

PLoS ONE
Multidisciplinary
2014English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy